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A B S T R A C T
C-Cbl-associated protein (CAP), also known as Sorbin and SH3 domain-containing protein 1 (Sorbs1) or ponsin,
an adaptor protein of the insulin-signalling pathway, mediates anti-viral and anti-cytotoxic protection in acute
viral heart disease. In the present study we describe a novel protective immuno-modulatory function of CAP in
inflammation.
Among the three members of the Sorbs family of adapter molecules, which include CAP (Sorbs1), ArgBP2
(Sorbs2), and Vinexin (Sorbs3), CAP consistently down-regulated the expression of pro-inflammatory cytokines
in mouse fibroblasts, cardiomyocytes, and myeloid-derived leukocytes, after Toll-like receptor (TLR) stimula-
tion. Upon the same TLR stimulation, ArgBP2 partially down-regulated pro-inflammatory cytokine production in
mouse fibroblasts and cardiomyocytes, while Vinexin rather promoted their production. Mechanistically, CAP
limited pro-inflammatory cytokine expression by suppressing the phosphorylation of Inhibitor of kappa B (IκB)
kinase (Iκκ)-α and Iκκ-β and their downstream NF-κB-dependent signalling pathway. Molecular affinity between
CAP and Iκκ-α/ Iκκ-β was necessary to block the NF-κB pathway. The CAP-dependent inhibitory mechanism - in
vivo exclusively IL-6 inhibition - was confirmed after collecting blood from mice with systemic inflammation
induced by lipopolysaccharide (LPS) and in the heart tissue collected from mice infected with the cardiotropic
Coxsackievirus B3 (CVB3).
Taken together, CAP down-regulates pro-inflammatory cytokines by interfering with the normal function of
the NF-κB pathway. The promotion of CAP production could support the development of new strategies aiming
to limit excessive and detrimental activation of the immune system.
1. Introduction
Infections trigger the innate immune system through Toll-like re-
ceptors (TLRs) and RIG-I-like receptors (RLRs), promoting antigen
presenting cells (APC) to produce pro-inflammatory cytokines, such as
IL-6 and TNF-α, which in turn induce acute phase proteins [1,2]. Ex-
tensive activation of pro-inflammatory innate pathways leads to self-
protein release, tissue damage, and ultimately autoimmunity or general
hyperinflammatory conditions, such as cytokine-release syndrome
(CRS) [3–6].
The sorbin homology (SoHo) family of adapter and scaffold proteins
consists of three proteins: CAP, also known as Sorbin and SH3 domain
containing 1 (Sorbs1), ArgBP2, also known as Sorbs2, and Vinexin, also
known as Sorbs3 [7]. All Sorbs proteins are highly expressed in heart
tissue, skeletal muscle, adipose tissue, and cells of the immune system,
functioning as SH3-domain-mediated adaptors of scaffolding molecules.
CAP, together with nectin and afadin, composes the NAP cell-cell ad-
hesion system [8]. CAP modulates cell adhesion, migration, cytoske-
leton reorganisation, membrane trafficking, and intracellular signalling
[7,9,10]. A protective anti-viral function of CAP in Coxsackievirus B3
(CVB3)-induced myocarditis has been also discovered [11]. CAP pro-
motes type I interferon production and at the same time limits cytotoxic
cytokine release, tuning a balanced and non-detrimental anti-viral re-
sponse. These data point toward a potential regulatory role of CAP in
the innate immune system. In LPS-induced sepsis, regulation of ArgBP2
by the micro RNA miR-21-3p contributes to cardiac dysfunction in
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affected mice, suggesting that ArgBP2 may have a detrimental function
in heart inflammation [12]. On the other side, the Vinexin isoform
Vinexin-β has been shown to promote inflammation by inducing NF-κB
activation and cytokine production in a mouse model of myocardial
infarction and also in a mouse model of atherosclerosis [13,14].
Pathogen- and damage-associated molecular patterns (PAMPs and
DAMPs, respectively) are recognized by different surface and cyto-
plasmic pattern recognition receptors (PPRs), such as TLRs and RLRs.
Downstream of these receptors, the NF-κB pathway is activated and
regulates the expression of pro-inflammatory cytokines, such as Il-6,
Tnf-α, and Ip-10 [15]. The adapter protein MyD88 promotes phos-
phorylation of the kinases IRAK1, IRAK2, and IRAK4 upon TLR sti-
mulation (except for TLR3), which then dissociate from MyD88 and
associate with the ubiquitin ligase TRAF6 [16]. The complex made up
of TAK1, TAB1, TAB2, and TAB3 is activated by the free lysine poly-
ubiquitin chain and phosphorylates IκB kinase (Iκκ)-β [17]. The Iκκ
complex, which is composed of Iκκ-α, Iκκ-β, and Iκκ-γ, phosphorylates
the inhibitory κB (IκB) protein, which undergoes proteosomal de-
gradation thereby promoting nuclear translocation and phosphoryla-
tion of NF-κB, which activates the transcription of pro-inflammatory
cytokines [18].
Since the role of CAP in inflammation has never been elucidated, in
this study we figured out how proteins of the Sorbs family of adapter
proteins regulate NF-κB-dependent production of pro-inflammatory
cytokines by using different primary cells and a cardiac cell line.
Furthermore, we confirmed the anti-inflammatory function of CAP in
vivo.
2. Materials and methods
2.1. Mice
CAP−/− C57Bl/6 mice, also known as Sorbs1−/− mice, were pre-
viously described in references [10,11]. All animal experiments were
conducted in accordance with the Animal Care Committee of the Uni-
versity of Zurich. Lipopolysaccharides (LPS, Sigma-Aldrich) at a con-
centration of 30 mg/kg body weight was intraperitoneally injected into
CAP+/+ and CAP−/− C57Bl/6 mice. Two hours later blood was col-
lected from the tail vein into serum tubes for cytokine measurement by
ELISA. Viral myocarditis was induced as previously described [11].
2.2. Cells, viruses, and plasmids
Mouse embryonic fibroblasts (MEF) were isolated from embryos at
day 13.5 of gestation. Bone marrow-derived dendritic cells (BMDC) and
bone marrow-derived macrophages (BMM) were cultivated as pre-
viously described [6,19]. For mouse neonatal fibroblasts (MNF), the
ventricles of 1-day old newborns were prepared as previously described
[11,20]. Briefly, heart ventricles were minced in small pieces and then
digested with trypsin (0.8 mg/ml). Ventricular cell suspensions were
plated for two hours at 37 °C to allow the MNF to attach to the plate.
Cells in suspension were removed and MNF were washed several times
with warm PBS before using them for experiments. HL-1 cells were
maintained in Claycomb medium (Sigma) and expanded in 75 cm2
flasks pre-coated with 5 µg/ml fibronectin (Sigma) and 0.02% gelatin
(Sigma) as previously described [21]. HEK-Blue-hTLR4 cells with the
inducible SEAP (secreted embryonic alkaline phosphatase) reporter
gene and the HEK-Blue Detection medium were purchased from In-
vivogen and used according to the manufacturer’s protocol. The car-
diovirulent CVB3 (Gauntt strain) and the vesicular stomatitis virus
(VSV) have been described previously [11].
2.3. siRNA and plasmid transfection
For knockdown experiments, CAP (catalog number SI01429106),
ArgBP2 (catalog number SI00872221) and Vinexin (catalog number
SI01417206) siRNAs were purchased from Qiagen. The AllStars Neg.
Control siRNA (catalog number 001027281, Qiagen) was used as
siMock control, as previously described [21]. For transfection, 1 × 105
cells were plated in 12-well plate with 1 ml supplemented Claycomb
medium. Cells were transfected with 25 pmol siRNA and RNAiMAX
(Invitrogen) according to the manufacturer’s protocol.
The FLAG-tagged CAP-WT and the CAP-ΔSH3 vectors, as well as the
empty control vector, were previously described [11]. Transfection of
106 HEK cells was performed with the calcium phosphate precipitation
method as previously described [21].
2.4. Quantitative RT-PCR (qRT-PCR)
To measure cytokine expression at the RNA level, RNA was isolated
with Trizol Reagent (Invitrogen) according to the manufacturer’s pro-
tocol. Reverse transcription was performed with 1 µg RNA. The 2−ΔΔCt
method was used for qRT-PCR gene expression analysis. Genes of in-
terest were compared with the housekeeping gene GAPDH. Used pri-
mers have been previously described [20].
2.5. Cytokine measurement
For cytokine concentration measurements, two different methods
were used. A screen of ten cytokines was performed with the Cytometry
Bead Array (CBA) LEGENDplex Mouse Inflammation Panel
(BioLegend), which included IL-1β, IL-6, IL-10, IL-12p70, IL-17A, IL-23,
IFN-γ, TNF-α, GM-CSF, and MCP-1. The CBA were analyzed on a BD
FACSCanto II. Commercially available ELISA Development Kits
(PeproTech) were used to measure IL-6, TNF-α, and CCL5 (RANTES)
after specific cell stimulations.
2.6. Western blot analysis and immunoprecipitation
Cell lysates were separated using NuPAGE Novex Bis-Tris gel
(Invitrogen), transferred on PVDF membrane (Roche Diagnostics), and
then immunoblotted with specific antibodies. Bands were visualized
with a Licor scanner. For immunoprecipitation, Dynabeads Protein G
(Invitrogen) were used according to the manufacturer’s instructions.
FLAG-tagged proteins were immunoprecipitated using anti-DDK Tag
(L5) Affinity Gel (BioLegend).
2.7. Immunofluorescence staining
HeLa cells previously transfected with the FLAG-tagged CAP-WT
vector were first fixed with 4% paraformaldehyde and then permeabi-
lized with 0.2% Triton X-100. Blocking was performed with PBS con-
taining 1% BSA and 0.2% Triton X-100. Anti-NF-κB p65 antibodies
(dilution 1:250) and anti-FLAG antibodies (dilution 1:200) were in-
cubated overnight at 4 °C. Secondary anti-rabbit AlexaFluor488 anti-
bodies for NF-κB p65 and secondary anti-goat PE antibodies for FLAG
were incubated at room temperature. Vectashield counting solution
with DAPI was used to cover the slides and stain the nuclei. Cells were
observed with a Leica fluorescent microscope.
2.8. Reagents
High molecular weight (HMW) Polyinosinic-Polycytidylic acid
(PolyIC), low molecular weight (LMW) PolyIC, and the imidazoquino-
line R848 were purchased from Invivogen. LPS and CpGs were pur-
chased from Sigma. Antibodies to Iκκ-α/β, phosphorylated-Iκκ-α/β (p-
Iκκ-α/β), Iκκ-α, Iκκ-β, Iκκ-γ, NF-κB p65, NF-B p-p65 (detects phos-
phorylation at serine 536 (Ser536)), p38, p-p38, ERK1/2, p-ERK1/2,
MyD88, and IRAK-M were purchased from Cell Signaling Technology.
Antibodies to IκB-α and GAPDH were purchased from Santa Cruz
Biotechnology. Antibodies to FLAG were purchased from Sigma-
Aldrich.
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2.9. Statistics
Data were analyzed with 2-way ANOVA and Bonferroni post hoc
testing. Statistical analysis was conducted using the Prism 6 software
(GraphPad Software). All data were expressed as mean ± s.d.
Differences were considered statistically significant for P < 0.05.
3. Results
3.1. CAP (Sorbs1) and ArgBP2 (Sorbs2), but not Sorbs3 (Vinexin), repress
IL-6 and partially TNF-α expression in vitro
To identify which members of the Sorbs family may regulate in-
flammatory cytokine expression, each Sorbs member was knocked
down by transfecting specific small-interfering RNA (siRNA) in MEF,
HL-1 cardiomyocytes, and MNF. Knockdown efficiency is shown in
Supplementary Fig. 1A and B. LPS stimulation was used to activate the
TLR/NF-κB pathway. In MEF, CAP and ArgBP2 knockdown resulted in
increased Il-6 and Ip-10 RNA expression, while Tnf-α RNA levels were
significantly higher only upon CAP knockdown (Fig. 1A). Vinexin, on
the contrary, showed opposite results. Indeed, upon Vinexin knock-
down, Il-6 and Ip-10 RNA expression was significantly reduced com-
pared to siMock-treated MEF (Fig. 1A). Induction of cytokine expres-
sion in HL-1 cardiomyocytes, as previously shown, was only achieved
after co-stimulation with LPS and IFN-γ [21]. LPS alone or IFN-γ alone
were not effective, since HL-1 cardiomyocytes did not express any de-
tectable inflammatory cytokine [21]. In transfected HL-1 cardiomyo-
cytes co-stimulated with LPS and IFN-γ, Il-6 and Tnf-α RNA expression
was increased after CAP and ArgBP2 knockdown, while Vinexin showed
similar levels as the siMock-transfected cells (Fig. 1B). Ip-10 RNA ex-
pression in HL-1 cells was inconsistently down- and up-modulated after
CAP, ArgBP2, and Vinexin knockdown (Fig. 1B). In LPS-stimulated
MNF cells, Il-6 expression was higher only after CAP knockdown, while









Fig. 1. CAP and partially ArgBP2, but not
Vinexin, inhibit Il-6 expression in knocked
down cells. (A) CAP, ArgBP2, and Vinexin
knockdown with siRNA in MEF stimulated
with LPS for the indicated times.
Transcription of the pro-inflammatory cyto-
kines Il-6, Tnf-α, and Ip-10 was determined
by real-time RT-PCR. (B-C) CAP, ArgBP2,
and Vinexin knockdown with siRNA in HL-1
cells (B), and CAP and Vinexin knockdown
with siRNA in MNF (C) stimulated with LPS
and IFN-γ (HL-1 cells) or with LPS (MNF) for
the indicated times. Transcription of the pro-
inflammatory cytokines Il-6, Tnf-α, and Ip-10
was determined by real-time RT-PCR. (D)
CAP, ArgBP2, and Vinexin knockdown with
siRNA in MEF stimulated with LPS for the
indicated times. Concentrations of IL-6 and
TNF-α in supernatants collected at the in-
dicated times was determined by ELISA.
From A to D: means ± s.d. and values
measured form one out of three independent
experiments performed in duplicates are
shown. *P < 0.05, **P < 0.01,
***P < 0.001 for siCAP vs. siMock,
siArgBP2 vs. siMock, or siVinexin vs.
siMock. +P < 0.05, ++P < 0.01, ++
+P < 0.001 for siCAP vs. siArgBP2.
#P < 0.05, ##P < 0.01, ###P < 0.001 for
siCAP vs. siVinexin. §P < 0.05, §§P < 0.01,
§§§P < 0.001 for siArgBP2 vs. siVinexin.
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regulated after CAP and Vinexin knockdown (Fig. 1C). Taken together,
these results indicate that CAP dampens the expression of Il-6 and Tnf-α
in all tested cells, ArgBP2 inhibits Il-6 and partially Tnf-α expression,
while Vinexin rather promotes Il-6 and Ip-10 expression in MEF and
MNF without affecting Tnf-α expression.
At the protein level, IL-6 measured in the supernatant of stimulated
MEF was useful to confirm that CAP and ArgBP2 knockdown resulted in
higher levels of IL-6 when compared to their siMock controls, while
TNF-α production was comparable among both groups (Fig. 1D). Vi-
nexin, on the contrary, slightly promoted IL-6 production (Fig. 1D).
Summarizing, IL-6 is reduced by CAP and ArgBP2, while Vinexin pro-
motes it. TNF-α production, on the contrary, is not affected by CAP,
ArgBP2, or Vinexin.
3.2. Acute phase cytokines are dampened by CAP in vitro upon various
TLRs and RLRs stimuli
To better understand how CAP modulates cytokine production at
the protein level, we investigated its function in cells belonging to the
immune system. Taking advantage of CAP knockout mice, BMDC were
cultivated from bone marrow cells as described in the materials and
methods section. Mature CAP+/+ and CAP−/− BMDC were then sti-
mulated for 24 h with two different concentrations of LPS. Cytokines
were evaluated in collected cell-free supernatants with a multiplex
array. Among ten pro- and anti-inflammatory cytokines tested, only IL-
1β and IL-6 were significantly increased in CAP−/− BMDC at both
tested LPS concentrations (Fig. 2A).
To further understand the function of CAP upon PRRs activation,
also MEF and BMM cells were harvested from CAP+/+ and CAP−/−
mice. Upon stimulation with various TLRs and RLRs agonists, IL-6 was
consistently over-expressed in CAP−/− cells when compared to CAP+/
+ cells (Fig. 2B and Suppl. Fig. 2A). Similarly, upon infection of BMDC
with CVB3 and vesicular stomatitis virus (VSV), which are two RNA
viruses, IL-6 production was significantly higher in CAP−/−-infected
cells compared to CAP+/+-infected cells. TNF-α production was sig-
nificantly increased in CAP−/− MEF only upon PolyIC stimulation and
in CAP−/− BMDC only after CVB3 infection when compared to their
CAP+/+ counterparts (Fig. 2C and E). Significantly higher CCL5 ex-
pression was also observed in CAP−/− BMDC just after VSV infection
compared to CAP+/+ BMDC (Suppl. Fig. 2B and C). These results in-
dicate that CAP consistently down-regulates IL-6 but just partially
controls the expression of other acute phase cytokines.
3.3. CAP hampers the NF-κB pathway
The major regulator of Il-6 expression is the transcription factor NF-
κB [15,22], which translocates into the nucleus following phosphor-
ylation and subsequent proteasomal degradation of the inhibitory κB
(IκB) protein [23]. Therefore, we aimed to figure out whether CAP and
ArgBP2 may influence the inflammatory signalling pathway triggered
by TLR4 stimulation that eventually leads to NF-κB activation. To this
end, we transfected MEF and HL-1 cells with CAP siRNA, ArgBP2
siRNA, or mock siRNA, and then measured phosphorylation of proteins
of the canonical NF-κB pathway before and after TLR4 stimulation. The
NF-κB pathway was consistently up-regulated in the absence of CAP,
but only partially in the absence of ArgBP2, suggesting a predominant
role of CAP as limiting factor of pro-inflammatory TLR signalling
(Fig. 3A, B and Suppl. Fig. 3A).
Given the observed differences in TLRs- and RLRs-induced pro-in-
flammatory cytokines in the presence or absence of CAP, we next aimed
to confirm the inhibitory role of CAP also in CAP-knockout cells. CAP+/
+ and CAP−/− BMDC were stimulated in vitro with LPS, while CAP+/+
and CAP−/− MEF were infected with CVB3. In both cases, increased or
extended phosphorylation of NF-κB- and MAP Kinasae-related proteins
was observed in CAP−/− cells compared to CAP+/+ cells (Fig. 3C and
D). In addition, HEK293 cells, which were first transfected with a CAP-
expressing vector and then stimulated with transfected high molecular
weight (HMW)-PolyIC or low molecular weight (LMW)-PolyIC, showed
reduced NF-κB p65 and ERK1/2 phosphorylation when compared to
mock-transfected HEK293 (Fig. 3E). Taken together, these results in-
dicate that CAP inhibits both the NF-κB and the MAP Kinase signalling
pathways in different cells after various stimuli.
To demonstrate that CAP limits NF-κB p65 activation and nuclear
translocation, HeLa cells were first transfected with FLAG-tagged CAP
plasmid and then stimulated for 30 min with PolyIC for detection of NF-
κB p65 by immunofluorescence. In some HeLa cells the CAP plasmid
was not transfected, therefore these untransfected cells represented the
internal control. After PolyIC stimulation, CAP-transfected HeLa cells
did not overexpress NF-κB p65 in the nucleus, while untransfected cells
showed increased NF-κB p65 fluorescence in the nucleus, demon-
strating that CAP limits NF-κB p65 activation and nuclear translocation
(Fig. 4).
3.4. CAP binds to Iκκ-α and Iκκ-β
It is known that CAP binds to the RLR receptor MDA5 and to MyD88
after CVB3 infection, upregulating the phosphorylation of IRF3 in viral
myocarditis [11]. On the other side, it is not yet known whether CAP
aggregates with any protein of the NF-κB pathway upon LPS stimula-
tion. Therefore, we transfected HEK293 and HeLa cells with a FLAG-
tagged vector encoding human CAP. After pulling down CAP, we ob-
served that only Iκκ-α and Iκκ-β complexed with CAP before and after
stimulation (Fig. 5A and Suppl. Fig. 3B). In addition, we used an ex-
pression vector encoding CAP that lacked its SH3 domains. Interest-
ingly, only full-length CAP, but not CAP depleted of its SH3 domains,
co-immunoprecipitated with Iκκ-α and Iκκ-β, suggesting that its SH3
domains are necessary for this interaction (Fig. 5A and Suppl. Fig. 3B).
The complex formation of CAP with Iκκ-β was further analyzed in
HEK cells over-expressing human TLR4 (HEK-hTLR4). After transfec-
tion or co-transfection of vectors expressing full-length CAP and Iκκ-β
into HEK-hTLR4 cells, activation of NF-κB was reduced in LPS-stimu-
lated CAP/Iκκ-β-co-transfected cells when compared to LPS-stimulated
cells transfected only with Iκκ-β or with an empty control vector
(Fig. 5B), suggesting that CAP can directly dampen the NF-κB pathway
by limiting the effect of Iκκ-β.
3.5. CAP represses IL-6 in mice challenged with LPS and in the heart of
CVB3-infected mice
To confirm the CAP-dependent up-regulation of IL-6 in vivo, we
challenged CAP+/+ and CAP−/− C57Bl/6 mice with LPS or with the
CVB3 virus. After LPS-induced septic shock, only IL-6 was significantly
increased in sera of CAP−/− mice compared to CAP+/+ control mice
(Fig. 6A). Since CVB3 has a particular tropism for heart tissue, hearts
from CVB3-infected mice were analyzed for cytokine expression at the
RNA level by quantitative real-time PCR. Ten days after CVB3 infection,
which corresponds to the inflammatory phase of viral myocarditis in
susceptible C57Bl/6 mice, hearts were collected and processed to
analyze RNA expression. Il-6, but not Il-1β, Tnf-α or Ip-10 was sig-
nificantly increased in heart tissue of infected CAP−/− mice compared
to CAP+/+ control mice (Fig. 6B). It is worth to notice that C57Bl/6
mice infected with the CVB3 virus do not develop autoimmune myo-
carditis, meaning that the increased Il-6 expression observed in the
heart at day 10 was not caused by heart-specific autoimmune cells.
Taken together, these results demonstrate that CAP suppresses IL-6 in
innate immune responses in vivo, supporting the immunomodulatory
function of CAP observed in vitro.
4. Discussion
In this study we showed for the first time the role of CAP in in-
flammation. In addition, we observed that ArgBP2 and Vinexin partially
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modulate inflammatory responses. We found that CAP specifically
limited the expression of the pro-inflammatory cytokine IL-6 and par-
tially TNF-α in mouse myeloid-derived cells, fibroblasts, and cardiac
cells in vitro and exclusively IL-6 in vivo. CAP down-regulated IL-6 by
binding to Iκκ proteins and then, after inhibiting their downstream
signalling pathway, inhibited NF-κB activation (Suppl. Fig. 4).
The NF-κB pathway is activated in response to TLRs and RLRs
agonists. Other pathways, such as the MAP Kinase pathway, selectively
enhance the accessibility of NF-κB to specific promoters, contributing to
Il-6, Il-8, and Il-12 gene expression [24]. Similarly, other transcription
regulators of the IκB family, such as IκBNS and IκBς, selectively mod-
ulate binding of NF-κB to the promoters of Il-6 and Il-12 [25]. In our
study we found a general reduction of IL-6 production in the presence
of CAP and in part in the presence of ArgBP2, which reflected the lower
levels of phosphorylated NF-κB p65. Nevertheless, we observed that
induction of several other pro-inflammatory cytokines was almost in-
dependent of CAP. We therefore exclude that CAP directly influences
the transcriptional function of NF-κB, but rather it may interact with
proteins upstream of NF-κB. CAP has been shown to be an adaptor
protein modulating membrane trafficking, intracellular signalling, and
cytoskeleton [7,9]. In our pull-down experiments, we observed that
CAP co-precipitated with Iκκ-α and Iκκ-β, but not with other proteins
that usually aggregate with them, such as Iκκ-γ. Impaired or depleted








Fig. 2. CAP inhibits the pro-inflammatory cytokine IL-6 in vitro. (A) Ten pro- and anti-inflammatory cytokines were measured by a Cytometric Bead Array (CBA) in
CAP+/+ (black squares) and CAP−/− (white squares) BMDC after stimulation with 0.1 µg/ml LPS or 1 µg/ml LPS. Supernatants were collected after 24 h. (B-C) IL-6
(B) and TNF-α (C) were measured by ELISA in CAP+/+ (black bars) and CAP−/− (white bars) MEF and BMDC after stimulation with 10 ng/ml PolyIC, 1 µg/ml LPS,
2.5 µg/ml R848, 1 µg/ml CpG, or left untreated for TLR activation or transfected with 1 ng/ml HMW PolyIC or 1 ng/ml LMW PolyIC for RLRs activation.
Supernatants were collected after 24 h, while cells were harvested after 6 h for RNA extraction and measurement by qRT-PCR. (D-E) CVB3 and VSV, both at a
concentration of 1 MOI, were used for direct in vitro infection of BMDC. After 6 h and 24 h, IL-6 (D) and TNF-α (E) were analyzed in supernatants by ELISA and at the
RNA level by qRT-PCR. UT, untreated. UN, uninfected. n.d., not detected. Data are representative for three experiments performed in triplicates (mean, s.d.).
*P < 0.05, **P < 0.01.
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Fig. 3. CAP reduces phosphorylation of members of the NF-κB pathway. (A-B) Total cell lysates from Mock-, CAP-, or ArgBP2-knocked down MEF (A) and HL-1 cells
(B) stimulated with LPS alone or co-stimulated with LPS and IFN-γ, respectively, for 10, 30, and 120 min. The NF-κB pathway was analyzed by immunoblotting with
the indicated antibodies. (C) Immunoblot analysis of phosphorylated (p)-Iκκ-α/β and total Iκκ-α/β, as well as p-p38 and total p38, in CAP+/+ and CAP−/− MEF
stimulated with 1 µg/ml LPS for the indicated times. GAPDH was used as an internal loading control. (D) Immunoblot analysis of p-Iκκ-α/β, total Iκκ-α/β, p-p65, total
p65, p-ERK1/2, total ERK1/2, p-p38, and total p38 in CAP+/+ and CAP−/− MEF infected with 1 MOI CVB3 for the indicated times. GAPDH was used as an internal
loading control. (E) Immunoblot of p-p65, total p65, p-ERK1/2, and total ERK1/2 in HEK293 cells transfected with FLAG-tagged CAP-encoding plasmid or control
mock plasmid 24 h before stimulation with 1 ng/ml transfected HMW PolyIC or LMW PolyIC for the indicated times. CAP-FLAG was used as plasmid transfection
control, GAPDH as internal loading control. Data are representative of one out of two experiments.
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inflammatory cytokine expression upon TLR activation [18]. It is
known that upon TLR activation, the catalytic Iκκ-α and Iκκ-β kinases
and the regulatory protein Iκκ-γ bind together to make the Iκκ complex
[26]. However, it has been recently described in hepatocarcinogenesis
and inflammation that Iκκ-γ works in an Iκκ-α/Iκκ-β-independent
manner [27]. A possible explanation for the lack of interaction between
CAP and Iκκ-γ may be the inhibition of the interaction between Iκκ-α/
Iκκ-β and Iκκ-γ, as demonstrated by using amino acid sequence NEMO-
binding domain (NBD) [28]. It is likely that CAP, by binding to Iκκ-α/
Iκκ-β, may mask the binding domains used by Iκκ-γ to complex with
Iκκ-α/Iκκ-β, thus dampening the pro-inflammatory NF-κB pathway and
repressing IL-6 production.
CAP-dependent inhibition of IL-6 was not exclusively observed after
stimulation of membrane-bound TLRs. Also upon stimulation of the
cytosolic RLRs receptors MDA5 und RIG-I, which sense intracellular
HMW and LMW PolyIC, respectively, IL-6 was significantly increased in
the absence of CAP. In addition, after viral infection with CVB3 and
VSV, whose RNAs typically sense MDA5 and RIG-I, respectively, IL-6
was significantly increased in CAP-deficient cells. We previously ob-
served that CAP binds to MyD88 and MDA5 after viral infection of HeLa
cells with CVB3 [11]. In the present study CAP complexed with Iκκ-α
and Iκκ-β upon LPS stimulation in MEF and upon co-stimulation with
LPS and IFN-γ in HL-1 cells, suggesting that CAP controls the NF-κB
pathway in different ways. Indeed, when membrane bound TLR4 is
sensed, CAP inhibits excessive IL-6-mediated inflammation, dampening
the production of detrimental acute phase proteins, while when cyto-
solic RLRs are sensed, CAP simultaneously dampens IL-6 expression
while promoting anti-viral protection by increasing type I interferon
production.
Some variations were observed in the cells used to elucidate the
function of CAP. In MEF, for example, CAP, but not ArgBP2 and
Vinexin, consistently regulated the expression of Il-6, Tnf-α, and Ip-10
while in HL-1 cells, both CAP and ArgBP2, but not Vinexin, controlled
Il-6, Tnf-α, and Ip-10 expression. On the other side, in cells belonging to
the immune system, such as dendritic cells, CAP regulated the expres-
sion of Il-6, and just marginally the expression of Tnf-α and Ccl5. Lower
expression of Il-6 in MEF in comparison with BMM upon LPS stimula-
tion has been explained after measuring different kinetics of NF-κB,
ERK, p38, and JNK phosphorylation between MEF and BMM [29]. Al-
though we also found different kinetics for protein phosphorylation in
the present study, CAP constantly reduced IL-6 production in all cells
used, while TNF-α and CCL5 were just partially affected.
It has been recently demonstrated in mice with viral myocarditis
that CAP protects the heart from detrimental anti-viral cytotoxic re-
sponses and increases the survival rate of infected CAP+/+ mice [11].
In the present study we showed that CAP repressed IL-6 expression in a
mouse model of LPS-induced shock and in a mouse model of CVB3-
induced viral myocarditis, which does not develop the autoimmune
phase, but only the initial innate inflammatory phase of the disease
[30]. The expression of other cytokines was independent of CAP, sug-
gesting that CAP specifically down-regulates IL-6 production in vivo.


















Fig. 4. CAP limits nuclear translocation of NF-κB p65 after stimulation.
Immunofluorescence staining of HeLa cells transfected with the FLAG-tagged
CAP-WT vector. Untransfected cells were used as an internal control for cells
that did not express CAP. Cells were left unstimulated or were stimulated with
PolyIC for 30 min and then stained with antibodies detecting total NF-κB (green
fluorescence) and antibodies detecting FLAG-tagged CAP (red fluorescence).
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Fig. 5. CAP binds to Iκκ-α and Iκκ-β.
(A) HEK-hTLR4 cells were transfected
with FLAG-tagged CAP-WT or CAP-
ΔSH3 vectors, or an empty control
vector. Physical interactions of CAP or
of its mutated form CAP-ΔSH3 with
proteins of the NF-κB pathway were
analyzed by immunoprecipitation and
immunoblotting. One out of two in-
dependent experiments are shown. (B)
HEK-hTLR4 cells were transfected with
a vector expressing CAP (black
squares), with a vector expressing Iκκ-
β (grey rhombus), or co-transfected
with both vectors expressing CAP and
Iκκ-β (grey circles). An empty vector
was used as control (white squares).
Cells were stimulated with LPS for 0.5,
2, and 4 h. NF-κB activity was de-
termined by measuring the O.D. value
of the reporter gene. Data are re-
presentative of one out of two experi-
ments. ***P < 0.001 for CAP/Iκκ-β-
co-transfected cells vs. Iκκ-β-trans-
fected cells.
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These findings indicate the potential of CAP in suppressing excessive IL-
6-dependent inflammatory responses that can lead to adverse clinical
outcomes in patients with pre-existing immunological disorders. In-
deed, IL-6 and other pro-inflammatory cytokines that induce acute
phase proteins play a major role in hyperinflammatory conditions, such
as in cytokine-release syndrome (CRS). Typical hallmarks of CRS have
been observed in leukemic patients treated with chimeric antigen re-
ceptor-modified T (CAR-T) cells, that showed increased IL-6 produc-
tion, and in patients with respiratory virus infections, such as in in-
fluenza virus and corona virus diseases [4,5,31]. Currently, the
suggested therapeutic option to reduce IL-6 is the anti-IL-6 receptor
antibody Tocilizumab [31,32]. Other therapeutic strategies to avoid
CRS may be based on preventive modulation of the immune system. In
this case, CAP could be used as a therapeutic agent to prevent hyper-
inflammatory conditions.
Taken together, we demonstrate a novel function of CAP as a
modulator of the immune system. Our data show that CAP specifically
interacts with proteins of the NF-κB signalling pathway and hampers IL-
6 production. By enhancing CAP production, innate immune responses
could be balanced towards a favourable clinical outcome, limiting in-
flammation and reducing adverse organ damages.
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